润达医疗
(603108)
| 流通市值：105.28亿 | | | 总市值：105.28亿 |
| 流通股本：6.04亿 | | | 总股本：6.04亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,661,846,010.13 | 8,311,780,357.39 | 6,176,286,324.36 | 4,135,268,017.92 |
| 营业收入 | 1,661,846,010.13 | 8,311,780,357.39 | 6,176,286,324.36 | 4,135,268,017.92 |
| 二、营业总成本 | 1,695,369,724.19 | 7,994,783,190.57 | 5,921,641,266.47 | 3,899,503,794.9 |
| 营业成本 | 1,316,525,968.41 | 6,203,492,198.74 | 4,592,846,859.28 | 3,014,617,835.12 |
| 税金及附加 | 6,934,547.78 | 40,981,347.66 | 31,418,567.63 | 22,664,129.15 |
| 销售费用 | 178,199,424.07 | 840,777,045.98 | 651,353,240.05 | 435,947,854.03 |
| 管理费用 | 104,063,010.8 | 479,941,188.72 | 328,121,993.25 | 210,983,836.94 |
| 研发费用 | 25,747,739.45 | 116,156,442.1 | 81,276,813.53 | 56,527,225.98 |
| 财务费用 | 63,899,033.68 | 313,434,967.37 | 236,623,792.73 | 158,762,913.68 |
| 其中:利息费用 | 68,139,704.78 | 312,858,681.19 | 237,011,916 | 160,870,448.74 |
| 其中:利息收入 | 5,765,532.67 | 13,365,461.21 | 10,713,409.58 | 8,270,129.61 |
| 加:投资收益 | 20,673,577.45 | 109,820,881.18 | 97,818,515.41 | 70,425,376.62 |
| 资产处置收益 | 645,775.8 | 11,463,482.16 | 5,542,547.12 | 2,958,813.52 |
| 资产减值损失(新) | -70,183.53 | -36,170,132.75 | -3,691,816.63 | -130,657.5 |
| 信用减值损失(新) | -44,888,893.6 | -81,714,124.65 | -112,898,735.77 | -86,987,136.6 |
| 其他收益 | 8,056,159.19 | 33,662,573.6 | 17,031,776.28 | 10,187,777.08 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -49,107,278.75 | 354,059,846.36 | 258,447,344.3 | 232,218,396.14 |
| 加:营业外收入 | 908,322.37 | 622,456.3 | 8,537,310.41 | 7,427,130.34 |
| 减:营业外支出 | 527,290.34 | 9,140,103.78 | 5,999,558.01 | 2,823,176.02 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -48,726,246.72 | 345,542,198.88 | 260,985,096.7 | 236,822,350.46 |
| 减:所得税费用 | 19,136,755.54 | 156,084,177.83 | 118,882,570.14 | 84,546,059.93 |
| 六、净利润 | -67,863,002.26 | 189,458,021.05 | 142,102,526.56 | 152,276,290.53 |
| 持续经营净利润 | -67,863,002.26 | 189,458,021.05 | 142,102,526.56 | 152,276,290.53 |
| 归属于母公司股东的净利润 | -69,258,725.43 | 55,280,607.97 | 50,424,910.92 | 91,306,078.58 |
| 少数股东损益 | 1,395,723.17 | 134,177,413.08 | 91,677,615.64 | 60,970,211.95 |
| (一)基本每股收益 | -0.11 | 0.09 | 0.08 | 0.15 |
| (二)稀释每股收益 | -0.11 | 0.09 | 0.08 | 0.15 |
| 八、其他综合收益 | 61,323.97 | 2,915,308.12 | 2,111,576.37 | 1,540,851.18 |
| 归属于母公司股东的其他综合收益 | 56,518.06 | 2,564,784.67 | 1,897,427.7 | 1,378,999.78 |
| 九、综合收益总额 | -67,801,678.29 | 192,373,329.17 | 144,214,102.93 | 153,817,141.71 |
| 归属于母公司股东的综合收益总额 | -69,202,207.37 | 57,845,392.64 | 52,322,338.62 | 92,685,078.36 |
| 归属于少数股东的综合收益总额 | 1,400,529.08 | 134,527,936.53 | 91,891,764.31 | 61,132,063.35 |
| 公告日期 | 2025-04-26 | 2025-04-26 | 2024-10-30 | 2024-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |